Skip to content

Effects of the ABCA1 inducer R3R01 on albuminuria levels in diabetic kidney disease

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511484-29-00
Acronym
R3R01-DKD-201
Enrollment
60
Registered
2024-07-11
Start date
2024-10-09
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic kidney disease

Brief summary

Urinary albumin-to-creatinine ratio (UACR) (Change from randomization to end of treatment at 3 months)

Detailed description

Measured GFR with plasma clearance of 99Tc-DTPA or eGFR measured with the CKD-EPI equation based on creatinine and/or cystatin C, 24 hours ambulatory blood pressure, Plasma PK parameters of R3R01

Interventions

DRUGTechnescan DTPA Radiofarmaceutisk præparationssæt
DRUGPlacebo

Sponsors

River 3 Renal Corp.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Urinary albumin-to-creatinine ratio (UACR) (Change from randomization to end of treatment at 3 months)

Secondary

MeasureTime frame
Measured GFR with plasma clearance of 99Tc-DTPA or eGFR measured with the CKD-EPI equation based on creatinine and/or cystatin C, 24 hours ambulatory blood pressure, Plasma PK parameters of R3R01

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026